{
  "document_id": "e2549b62",
  "zip_file": "kjnw0257.zip",
  "category": "Presentations",
  "content_file": {
    "file_name": "kjnw0257.pdf",
    "file_path": "Presentations/kjnw0257.zip/kjnw0257.pdf",
    "extracted_text": "=== Page 1 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 1 Image 1 (OCR) ===\nTe\n\nMcKinsey Vi First cut doc\n& Company BEEEEEEEEE Numbers to be further refined\n\nYj\nyy\n\nCorporate\nperformance\ndiagnostics\n\nDiscussion document\nFeb 2020\n\n@endo\n\nOME DET AL ALD PROPER E TARY ot of\nfon ase Phas sole: a wilt abape: Pooper ssc PRG Kosi, 8 on ran es\nSb tyra x /\n\nMCK-MAAG-2630461\n\n=== Page 2 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 2 Image 1 (OCR) ===\nKey issues\n\n.\n\nOpioid: Company is facing litigation related to opioid overuse across many states in US Settled liabilities with\n\nPeete lara at ese er ererele crease stata a ee late et ase eal ela eal ele a eteialasreia.e.ctetai sleet eatsrereseraia a dnteaerelatarstetase.e1atarereresaserd\n\nOklahoma and case coming up with NY state Analyst estimate total potential liability range from USD 0 5B - 4 0B\n\nLegal\n\nRedacted\n\njee ses ese e tse inte area eaten eset a terest aera late rera Stele a erere a area. eieteatelei alerts arerelatesara areata aie lareiatea.eserearessteeseraterare\n\nia enn\n\nRedacted\n\noie a laa isisiareisialaim sistas itision isielaisisiaiainieieiaa fs iaiatafisiaiose sistas sialon isieiaefeielao ne isie lara sciaiateisisioe isto in icisio ps ieiela ne feiain nis ieinieisisin a icie!\n\nSov\n\nvn tou\n\nMcKinsey & Company\n\n2\n\nMCK-MAAG-2630461.000001\n\n=== Page 3 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 3 Image 1 (OCR) ===\nSummary\n\n° .\n\nfetetatmeeswararese'\n\nEndo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\npete sR Bind id\n\nRedacted\n\n(atmnwrere sae: S ia iera ale ie asereyermsoreses\n\nj growth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\nsetae tere areata case te ieretetoeseatdiatolat eine taretata athlete atelaeiea aetna ae atarare lai eiete iar esn aera inten ejecta arelntale.eiat arate inieiarn interne ereiareiatelaseseterare:\n\ncompany is facing large potential litigation liabilities\n\nRedacted\n\nlee rose eas a ier ees solar mees afore ye aterm ys ola ms aie rees a iereis siete ys oe ees alata ata mys ola ms ate mis oie eas siete ys oie e es calorie aia ie ela ae aie eee oie ais slat ess sie es e\n\nMcKinsey & Company\n\n3\n\n6 September 2020\n\nMCK-MAAG-2630461 .000002\n\n=== Page 4 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 4 Image 1 (OCR) ===\nSummary\n\n¢ Endo is well performing operationally with higher margins than peers. However, due to issues related to\n\nSia. Lisielelaiuiesaye tone a ieiaeieleisialeteioey\n\nRedacted\n\nopioid crisis, !\n\nmca rn sapere msare asain; aiatea.srase.e+arererere\n\nigrowth is negative, cash flow did not cover liabilities, debt is\n\nbelow investment grade and company is facing large potential litigation liabilities\n\nplate esata ta eraiaie arate is afaieia faimie aia ia ie era aie eraia ta aiaiasaafaie ies. efaieia ofa iaia- aia ia ie ara ate eraiasa aa.aseafaieis era ieia ofa ieia ernie ie ara ate arnia ss aacase aie\n\nRedacted\n\nieee terete ere terete reenter\n\narene eter eee erate eee ere ete ee ee a eR ee A ne nn ne A ne RR en RR Re RR ne Rn ne A nn eR ne ne nnn nie ene en ein mia einen ieeiaieimimieiermimrerereie:\n\nMcKinsey & Company\n\na\n\n6 September 2020\n\nMCK-MAAG-2630461 .000003\n\n=== Page 5 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 5 Image 1 (OCR) ===\nEndo’s share price has declined ~90% in last 5 years mainly driven by\n\nlegal challenges and underperformance\n\nEndo share price’\n\nUSD per share\n\n= seamen arm emie\n\n_ [revere rere rarer ererererer -\n\n120\n\nMar ‘16: Sued by FTC along\n\nwth others ‘or illegally blocking\n\nlower-cos: generic versions of\n\nRedacted\n\nRedacted\n\nRedacted\n\nthe Rrandeg. drugs Opana ER\n\n!\n\n|\n\n|\n\nang Redacted!\n\neietee\n\npiano mete etn em iatetm rina termed\n\n:\n\neine tetera aterm erred\n\n———————=\n\nae\n\nNavsmigmemtnarenige ces\n\nA Te Re\n\n80\n\npoate ere rerererererererererereress\n\nmine te terete ey\n\nJun ‘17: Sued by Ohio Asorney General\n\nalongwith ‘our other pharma companies ‘or\n\nRedacted\n\n‘heir alleged par: in dnung an opioid and\n\nPrescnpion painkiller overdose epidemic\n\n:\n\nLowi ini anim etapa re isielm ness iete re sas, -\n\ni\n\ni\n\n:\n\nRedacted |\n\nRedacted\n\n2\n\nYi\n\nNectmsevercieiases -\n\n!\n\nmieimiain rm imintnraimininrnteinvnd\n\n|\n\nthrough aggressive marke'ing ‘ac‘ics\n\nee ee ee\n\n40 -\n\nJun 17: FDA reques's.\n\npain medication, Opana\n\nEndo ‘o rerrove rs opioid\n\nRedacted\n\nER, ‘ror the marke:\n\n|\n\nSte taversieteversietevetsiets\n\n:\n\nJan 15\n\nJul 15\n\nJan 16\n\nJul 16\n\nJan 17\n\nJul 17\n\nJan 18\n\nJul 18\n\nJan 19\n\nJul 19\n\nJan 20\n\nt\n\n7A bet\n\n77\n\ns:\n\ny\n\nSAP Capla Tet rays s\n\nMcKinsey & Company\n\ni]\n\nMCK-MAAG-2630461 .000004\n\n=== Page 6 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 6 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnen Ene rn SEnE ESSENSE SEnE SSDS RENE SESE SEnE SESS SEnSSNE SESE SERS SESE SERSSnSSESnSEESSNSSESERSRESHSNSSRESHSSESIRSSNSSHSESSRESSESSSRESSSHSERSSRESSSESERSNSSHSRSSnSSOSSHSERSSSESOSSESSSESSSSSERSSNSSHSSESSRSSSSNSSRESNSSHSSESSRE SSSI SERSSESSHSnSSRSSHSSISSRSSNSSHSSSSSRESHSSNSTnSSNSSOSSRSSnSSESSNSTSSSNESESESERESSSSSTESSSESHSnSSEE SSSI SSSESNSSOSRSSRSSHSSNSESSNE SE SESSSE DESDE SRSONSSISS\n\nAAG-2630461.000005\n\n=== Page 7 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 7 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTenner SEnE ESSENSE SERS SNS SE REEDED SERS SSE SERENE SESE SERS SESS SERSSnSSESESEES DSSS SERSNESHSNSSRESHSSESERSSNSSESnSSEESNSSSSSRESSSSHSSESSRESSSESERSNSSHSESSnS SSDS SERSSSESOSSnSSSESSSSESEnSSSSHSSESSnSSSSSSSnESNSSISSESSEESSSESERSSESSHSESSEE SSDS SSSSNSSHSSASSRESH SSN SInSSNS SOS SRSSRESESSNSTSSNESESESSRESSSNSTESSSESHSnSSnSSNSEESSSESNSSNSERSSRSSHSSNSISESNE SE SRSSEESSSSESEESONSSISS\n\nAAG-2630461.000006\n\n=== Page 8 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 8 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTenner SEnE ESSERE SSE SEnE SSDS RENE SESE SEnE SESE SERSENE SESE SERS SESS SERSSnSSESnSEES SSDS SSRSNESHSEESSRESHSSESERSSNSSHSnSSRESSEESSRESSSHSSESSRESSSESERSESSHSRSSESSSSESERSSSESHSSESSSESSSSSERSSSSHSSESSRESOSSESSRESNSSHSSESSnESSSESEnSSNSSHSnSSRS SSDS SSnSNESHSSRSSSESHSSNSEnSSNSSHSSRSSRSSESSNSTSSSNESESESERESSSSSTnSSSESHSnSSESSNSEESSSISNSSSSERSSRSSHSSNSISSNE SE SEESSESSOSSESERSNSSISS\n\nAAG-2630461.000007\n\n=== Page 9 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 9 Image 1 (OCR) ===\nEndo's revenue profile has remained flat and declined since 2016 driven\n\nby both Branded and Gx segments\n\nEndo's Revenue evolution by segment, 2014-19, USD bn, as reported\n\nmista tet te crete terete terete reas\n\nieee tere eter terete re erate terete reer\n\nRedacted\n\nW@ US Branded - Specialty & Established Pharmaceuticals! _\n\n5 GJS Genenc Pharmaceuticals\n\ni wiererctaieseciniararsteiereciwiataciaiaves\n\nGrowth (2014-19),\n\nKey takeaway\n\nCAGR SE\n\nPaet_Coubeshi uh tthines_ Sarna\n\nf\n\n40\n\n8% p.a.\n\n10% p.a.\n\n| Redacted\n\neine teint eter terete reer\n\n33\n\n2\n\n35\n\nBranded Pharma portfolio\n\ndeclining, driven by loss of\n\n29\n\n29\n\n29\n\nNA\n\nmarketing exclusivity for\n\n|\n\ncertain drugs and voluntary\n\nwithdrawal of OPANA® ER\n\na\n\nfrom the market since\n\nFY2017\n\ntard reiatescéeineridaieversins ‘\n\n09\n\nat\n\nRedacted\n\n03\n\n05\n\n03\n\na\n\n20°4\n\n20°9\n\naime terete eter terete reread\n\nee\n\nRedacted\n\nMcKinsey & Company\n\n)\n\n[ee ee ee Ee Ee <\n\nMCK-MAAG-2630461 .000008\n\n=== Page 10 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 10 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEnE ESSER ENED S SERS ESSE SEnEnE SOS nSEnE SOS SE SERENE SESE SERS SESS SEnSSNS SES EASERS DSSS SSRSNESOSEESSRESHSSESERSSNSSESnSSSESSSESSRSSSSHSEESSRESSSESERSNSSHSnSSRSSESSESERSSNESOSSESSSESHSSNSEnSSSSHSSESSRSSSSSISSnESNSSUSSESSRESSSESERSESSHSnSSEESOSSESSSSNSSHSEASERESHSSISTnSSNSSUSSRSSRSSESSNSTSSSNESESESERESSSSSTESSSE SHS ASSESSHSSISSSISNSSOSERSSRSSHSSNSESESNE SE SESSESSSSSESEESNSSIS\n\nAAG-2630461.000009\n\n=== Page 11 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 11 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nCnn nen ne Sn SEnE ESSERE SSE SEnE ESSE SEnSnE SESE SEnE SESS SERSSNE SESE SERS SES SESERSSNSSESEASEES SSDS SSRSNESUSESSRESESSESERSSNSSHSESSRESSSSSSRSSNSSHSSESSRESSSESSRSNSSHSESSESSNSSSSERSSSESESSESSSESSSSSERSSSSHSSESSnSSSSESSnESNSSISEASSnE SSSI SERSSESSHSESSESSSSSSSRSSNSSHSSASERE SSSA SInSSNSSOSSnSSRSSESSNSTSSNESSSESERESSSSSSESSSESHSnSSEESHSENSSSESNSSSSRSSRSSHSSNSESSNE SE SRSSRSSSSSESEESONSSIS\n\n=== Page 12 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 12 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnen Ene rn SEnE ESSERE SSE SEnE OSS SE RENE SOS SEnE SESSA SERENE SESE SSNS SESS SERSSnSSESnSEES SSDS SERESnESOSESSRESHSSESIRSSNSSESRSSRESNSSESSRESNSSHSEESSRESHSSESERSNSSHSnSSES SOSH SERSSSSSESnSSSESSSSSERSSSSHSSESSRSSSSSSSSESNSSISSESSEE SOSH SERSESSHSnSSRESOSSSSSSSNSSHSSnSSRESH SSE SInSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTSSSSESHSnSSEESNSENSSSESNSSSSRSSRSSHSSNSISSNE SE SEESSRSDSSESERESNSSISS\n\n=== Page 13 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 13 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne Ene nS nSEnE ESSERE SSE SERE SSDS RENE SESE SERS SES SESERSSnE SESE SERS SESS SERSSnSSESnSEES SSDS SERSNESOSNSSRESHSSESERSSNSSESRSSSESSSESSRESSSHSERSSRESHSSNSERSNSSHSnSSESSSSN SERENE SES SnSSSESSSSSERSSSSHSSESSRSSSSESSRESNSSISEESSNESSSSESERSESSHSnSSESSSSESSSSNSSHSSnSSEESHSSASEnSSNSSUSSRSSRSSESSNSTSSNESESESERESHSSSSTESSSESHSnSSEESHSSESSSISNSSSSEnSSRSSHSSNSESSNE SE SESSRSSSSSESEESNSSISS\n\n=== Page 14 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 14 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena nr nSEnE ESSENSE SEnE SSS SERENE SESE SEnE SESS SERSSnE SESE SERS SESS SERSSnSSESESEES DSSS SERESRESUSEESSRESESSESERSSNSSESnSSRESSSESSRESSSHSEESSRESSSESERESNSSHSSESSnSSSSNSEnSSSE SES SESSSESSSSSERSSSSHSSESSnSSSSSESSRSSNSSUSEESSRESSSESERSNSSHSRSSEESOSSESSnSSNSSHSEASSSESNSSNSInSSNSSUSSRSSRESESSNSTSSNESESESERESSSSSTESSSESHSnSSESSHSEESESESNSSOSRSSRSSHSSNSISSNE SE SRSSRSSSSSESEESONSSIS\n\n=== Page 15 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 15 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne nner SEnE ESSER SEEDS SERS SOS SE RENE SSE SERE SES SE SERENE SESE SERS SOS SESERSSNS SES EESEES DSSS SSRSNESHSESSRESHSSESERSSNSSESnSSRESSSSSSRSSSSHSSRSSRE SOSH SERSNSSISESSESSSSESERSSSESOSSnSSSESSSSNSERSSSSHSSESSNSSSSESSnESNSSHSEASSRE SSSI SERSESSHSESSRSSHSSESSSSNESHSSASSRESSSESTnSSNSSUSSRSSRSSESSNSTSSSNESESESSRESHSSSSTSSSSESHSnSSESSNSSNSSSESNSSSSEnSSRSSHSSNSESSNE SE SRSSRSDESSESERSSSISS\n\n=== Page 16 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 16 Image 1 (OCR) ===\nERR ES\n\nRedacted\n\nTonner EnE DS nSEnE ES EnSE RSENS SSESEnESSSESERSSnE SO SnSSESSESSESESSSNSSESEESSRSSHSSISTnSSNSSESEISSEESISEISSRSNSSHSIESSEESHSSNSSRSSNSSHSSNSEEESHSENSSRSSNSSISSRSSRESHSSESERISNSSHSSRSSESSHSSNSERSNSSHSINSSSOSISSNSERSNSSHSnSSROSHSSNSIRSSNSSHSNSSEESHSSESERSSNSSHSnSSESSHSSESERSSNSSHSNSERESHSSNSENSNSSHSSRESEOSESEESTSSSNESHSESERESNSSNSTESSNESHSInSSESSHSENSSSESNSSOSEnSSEOSHSSISISSSNS SE SEESSES SSS DESEEEONSSO\n\n=== Page 17 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 17 Image 1 (OCR) ===\nere tetere.\n\nf]\n\nEndo also has large potential litigation liabilities upto ~USD\n\nperetese: <i\n\nRedacted\n\nEstimate\n\nLiability\n\n\"If we consider Oklahoma to be a “typical” state (28th in population and 29th in GDP). Endo’s settlement\n\nimplies a nationwide liability around $500M.“ — Gabelli. Jan 14°, 2020\n\nOpioid\n\n\"We estimate a fair value range of S2-4 based on our DCF (10% WACC. -1% terminal). using ~$3-4B\n\nopioid charges paid over 10 years.” — Guggenheim, Nov 5\", 2019\n\nieee tere eter eee re erate ete eee ete ee ee eR ee A ne RR ee A nn eR Rn RR RR RR nn A nn RR nein nn Rn ne a nn a ni ene ee einen einai nie eie erm eieieeiaiermi nite\n\nRedacted\n\nLinen eee ee ete ee ere ete a erate ete a ere ere ete ere ete ee a ee nn ee en nn ne nn nnn A ee A nn ne ee a eine nie nia eine nie nie einiaieieeia erm eieieeiarermrerererey -\n\nsor\n\nssp\n\nvila og Areal:\n\nrl\n\nvt\n\nMcKinsey & Company\n\n7\n\nMCK-MAAG-2630461 .000016\n\n=== Page 18 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 18 Image 1 (OCR) ===\nTo be further refined\n\nSummary\n\n|\n\n. _Endo i is well performin operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\nted\n\nBis Siaveys Sintete tere ste ciate ys-siarme ys a)\n\n“igrowth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\n“company is facing large potential litigation liabilities\n\nen ee a a ne ne a ne a ee a a an ne ee ee ee See Se eee Se\n\nRedacted\n\n( ereiwie aia mia aia la ie are aera aia araiasa afaiaia.e alae aiaie ie ara ieia aia aia era ata afacase araiajo. eral ia ara leia aia aia a iata ie era a ta araiase araiasa.eraia isa faieie ara lerao\n\nMcKinsey & Company\n\n18\n\n6 September 2020\n\nMCK-MAAG-2630461 .000017\n\n=== Page 19 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 19 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nCnn nen ne Sn SEnE ESSERE SSE SEnE ESSE SEnSnE SESE SEnE SESS SERSSNE SESE SERS SES SESERSSNSSESEASEES SSDS SSRSNESUSESSRESESSESERSSNSSHSESSRESSSSSSRSSNSSHSSESSRESSSESSRSNSSHSESSESSNSSSSERSSSESESSESSSESSSSSERSSSSHSSESSnSSSSESSnESNSSISEASSnE SSSI SERSSESSHSESSESSSSSSSRSSNSSHSSASERE SSSA SInSSNSSOSSnSSRSSESSNSTSSNESSSESERESSSSSSESSSESHSnSSEESHSENSSSESNSSSSRSSRSSHSSNSESSNE SE SRSSRSSSSSESEESONSSIS\n\n=== Page 20 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 20 Image 1 (OCR) ===\nFuture cash flows from operations would be used up to pay\n\nlitigation charges and interest expenses\n\nCumulative cash flow, FY2020-23, USD bn\n\nUpside case\n\nDownside case\n\niinet eter ete a erate er erate rer etere ete area re ere areata ererererereierererereie\n\nCFO betore interest i\n\nieee tere eter te eter rete eater e teeta re ere eter eie aie eieieieie ere ererereierereiere:\n\nRedacted\n\nA\n\npetite eerie ernie mieten niet miei mieten ieee\n\nAssumptions:\n\n& changes in WC\n\npeel eee tere eset ere: APN en SP ne at te earl arr ean a en ee aT ST ST TST ere TT mse m,\n\nLragation charges\n\n49\n\n=\n\nRedacted\n\nbese sese sense tesesninseinvasninieiniesninsniniasnmeninvnsnins\n\n!\n\nOpioid litigation liability estimated to range from\n\nUSD 500M In Upside case to ~USD 4.0B in\n\nDownside case (based on analyst reports).\n\nieee tere erent eter erent erate erate ererererereierereree:\n\nassumed to be repaid by FY2023\n\n\"\n\n\"\n\n\"\n\n\"\n\n\"\n\n\"\n\n\"\n\n\"\n\n\"\n\nRedacted\n\n\"\n\nRedacted\n\n\"\n\n\"\n\n\"\n\n\"\n\n\"\n\npe :\n\nLiner e re eee eee ete ete eee tee ere erecta re erate erate eee areata mere ieee ereieiereeieiererererereierereieia\n\ni\n\nScarce SRP olay ba\n\nMcKinsey & Company\n\n29\n\nim eles n le tam mie tormialesoemia te tareta les ci eiate lara esormin let ara aie toma lesormietetaemie tas cinta tela mala iormia le aia ate iotai ale ormin ta aoa ates ornate tamale tormiale tai ate tataialatormintntomatesormia taser m ale tormtatasamiatetarmata\n\nRedacted\n\nieee eter ete a erate re ete ere ere ere ee ern Rte ein ete eR eR RI ne Re RIA nn AIR nn A RR RIS eR RnR SIR nn A nn A Rn SIR nn An a a en ee nie aia nie a nin aia nina eiaaiaiaiaaeinieiaiaiemmimmimmimmmimmimrermiard\n\nMCK-MAAG-2630461.000019\n\n=== Page 21 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 21 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEnE ESSERE SSE SEnE SSDS nSnE SOS nSERE SOS SE SERENE SESE SSnSSES SE SERSSNSSESESEES SSDS SERESRESUSESSRESHSSESERSSNS SE SnSSEESSEESSRESSSHSSESSRESSSESSRSNSSHSEESSnSSHSSNSEnSSSESOSSESSSESSSESERSSSSHSSESSnSSSSESSRESNSSISEASSnE SSSI SERSSESSHSESSRESOSSESSnSNSSHSSASSEESHSSNSEnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSEESHSEESSSISNSSOSEnSSRSSHSSNSISSNE SE SESSEE DESDE SERSSSIS\n\nAAG-2630461.000020\n\n=== Page 22 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 22 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEn ESSERE SSE SEnE SSDS nSEnE SESE SERE SESE SERENE SESE SERS SESE SEESSnSSESESEES DSSS SERSRESHSEESSRESHSSESERSSNSSESnSSEESNSESSSSESSSHSEESSRE SOSH SERSNSSHSSRSSESSSSNSERSSSS SES SSSSSESSSSSEnSSSSHSSESSnSSSSSESSSESNSSISEESSnE SSSI SEnSSNSSHSESSRSSSSSSSSSNSSHSSnSSEESHSSNSEnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESH STRESSES SHOES SSSISNSSSSERSSRSSHSSESISESNE SE SnSSEE SS SSESEREOSSOS\n\n=== Page 23 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 23 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne nner SEnE ESSE n ERE SS SERS SOS SE RENE SOS nSEnE SESS SERSSNE SESE SERS SESS SERSSnSSESEESEEE SOSH SSRSNESISEESSRESHSSESIRSSNSSESnSSEESNSSESSRESSSHSERSSRESSSESSRISNSSHSRSSRSSSSESSnSSSSSESSESSSESSSSSERSSNSSHSSESSnSSS SE SSRESNSSISSESSRESSSESERSSESSHSESSRSSSSESSSSNSSHSSnSSRESHSSNSInSSNSSOSSRSSRSSESSNSTSSNESESESERE SSDS STESSSESHSnSSES SSSI SSSISNSSOSRSSRSSHSSNSISSNE SE SnSSES DESDE SEESOSSIS\n\nAAG-2630461.000022\n\n=== Page 24 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 24 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnen EnE rn SEnE ESSENSE SEnE SSSR EnE SESE SERS SES SE SERENE SE SEESSnS SESS SERSSNS SES EESEES DSSS SERSRESHSEESSRESHSSISERSSNSSESnSSRESNSSSSSRESSSHSEESSRESHSSESERSNSSHSRSSRSSHSSESERSSSESESSESSSESSSNSEnSSSSHSSESSRSSSSSSSnESNSSISEASSRESSSESERSESSHSRSSEESOSSESSSSNESHSEISSRESHSSNSInSSNSSUSSRSSRSSESSESTSSSNESESESERESHSSSSTESSSESHSnSSES SSSI SSSISNSSSSRSSRSSHSSNSISSNE SE SESSSESSSSESEEEONSSOS\n\nAAG-2630461.000023\n\n=== Page 25 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 25 Image 1 (OCR) ===\nAnalysts are concerned about Endo's ongoing opioid litigations,\n\nie ee ee eee eee te ere ee ee ee ere eee eee ere ere ere Mb areata eee einer eee ene ere meres,\n\nRedacted\n\nVici aja naa ye efaiaia, efaiaie aisle ia ara aie. nraiote- are c so roa ierese ele nyaiaie apaiaia nia ata. araiaja-niaajs.naiayeerai—\n\niota mtaiaies area yeefaiaiearaiaie- ara la ia ara aie-asaiota-araiase aaa ia.eraias 1\n\n‘\n\n@. We are becoming more positive on ENDP from an opioid standpoint,! i\n\nsate iarererererarare ata erate al araiarerelalarereaiaratarn mraiaeasarearmtarmiearmtnrarainy ‘\n\ni\n\ni\n\ni\n\ni\n\ni\n\ni\n\ni\n\nRedacted\n\nRedacted\n\ni\n\nbien eet eee eee ere tee ere ieee eit ee ieieeie eieieieieeiiereieimieieies Roo voces cere recente rere rete ere rere sere ere re sete rere rete se rere re sesererereseseses\n\nGabelli, 14 Jan 2020\n\nSoo epee a are ate eae a sre ese ate eretn esas a aa iera ea a = areata eae a are ase a ta asin esas eee ieee pe et = area\n\nSie eielave a ieiste eveiste eveieve etoile\n\natewtesei\n\nRedac\n\nrover\n\nRedacted\n\n|\n\ninl e IS ae isla le SiS elas lala Sit iala Sisisle Sitisle ei ale islet eis alae isiale Sisial a eisisie eitisie we ela eS\n\n‘However, ENDP’s!\n\nae\n\naed\n\nand ongoing opioid litigation/headline risk add unique risks that are challenging to handicap and have weighed on the stock\n\nRBC capital markets, 5\" Nov 2019\n\n§Petele cial Sle sie cin a ialaletsiatele otal GS a1inta Slat Sle cialele ciaiaie sialcle sisicie ataletese,\n\ndact\n\nmiei\n\nHowever, we continue to expect this dynamic to be\n\novarananowea by’ the « ongoing opioid saga, , which in our view remains a very significant risk given the company's branded\n\nSie a She te avetete: ciie late iSiale ate eetatNEINE Swe wtaiSin wieiete sia winiaiS ae haiela aii alelewimiaiDeietete icin!\n\nee\n\napes Portfolio/mkt s share\n\nri\n\ncted\n\nfelt ie ete er et er ete ee re ee eee Ieee eee mee memes mime\n\nRedacted\n\nJP Morgan, 5‘ Nov 2019\n\nSow\n\nvail\n\n1\n\nMcKinsey & Company\n\n25.\n\nMCK-MAAG-2630461 .000024\n\n=== Page 26 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 26 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nnena rn SEn ESSERE SSE SEnE SSDS RENE SESE SEnE SES SE SERENE SESE SERS SESS SEnSSNSSESESEES SSDS SERESRESHSASSRESESSESERSSNSSESnSSRESSSSSSRESSSHSEESSRESHSSESERSNSSHSSESSnSSSSESEnSSSS SOS SESSSESSSSSERSSNSSHSSESSnSSSSSSSSSESNSSISSASSEESSSESERSESSHSESSESSSSESSRSNESHSEASSRESHSSNSInSSNSSOSSRSSRSSESSNSTSSSnESUSESSRE SSDS STESSSESHSnSSESSNSEESSSESNSSOSEnSSRSSHSSNSESSNE SE SnSSEE DESDE SEESSSOSS\n\nAAG-2630461.000025\n\n=== Page 27 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 27 Image 1 (OCR) ===\nSummary\n\n¢ Endo is well performing operationally with higher margins than peers. However, due to issues related to opioid crisis,\n\ni\n\ncictaiate ate alata larala rere atte elec\n\nRedacted\n\nbps ah ee\n\nigrowth is negative, cash flow did not cover liabilities, debt is below investment grade and\n\ncompany is facing large potential litigation liabilities\n\npetite tte ier er ee er ee eee ems mm e memes mrmrmem mimes\n\nRedacted\n\nSeles esei aerate aera late are latecm ear erntaeiela este etetstalee ist aerea eaten ese aera ine ate a erate melee ereialararelateieteiaretna cle iarerateleseieieiereisteaseraterare!\n\nMcKinsey & Company\n\n27\n\n6 September 2020\n\nMCK-MAAG-2630461 .000026\n\n=== Page 28 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 28 Image 1 (OCR) ===\nERR ES\n\nRedacted\n\nTonner EnE DS nSEnE ES EnSEnSEnE SE SESEnESSSESERSEnESESnSSESSHSSESESSSNSSESESSRSSHSSISEnSSNSSUSEESSESSISSISSRESNSSHSInSSEESHSSNSIRSNSSHSSNSSEESHSENSSRISNSSHSSRSSRESHSSNSERISNSSHSTNSSESSHSSNSEnSNSSHSSNSSSOSHS=NSENSESSHSNSSNSSHSSNSIRESNSSHSENSSEESHSSESERSSNSSHSNSEESSHSSISSRSSNSSHSINSERESHSSNSInSNSSNSRESEOSHSSNSTSSSNESHSESERESNSSNSTESSNESHSInSSEOSNSENSSSESNSSOSERSSEESHSSESESSSNS DE SERSSES SES SESEEEONSSOSS\n\nAAG-2630461.000027\n\n=== Page 29 ===\nSource:  https://www.industrydocuments.ucsf.edu/docs/kjnw0257\n\n=== Page 29 Image 1 (OCR) ===\nBe ee ee ee\n\nRedacted\n\nTne rn SEnE ESSERE SSE SEnE SSDS nSnE SOS nSERE SOS SE SERENE SESE SSnSSES SE SERSSNSSESESEES SSDS SERESRESUSESSRESHSSESERSSNS SE SnSSEESSEESSRESSSHSSESSRESSSESSRSNSSHSEESSnSSHSSNSEnSSSESOSSESSSESSSESERSSSSHSSESSnSSSSESSRESNSSISEASSnE SSSI SERSSESSHSESSRESOSSESSnSNSSHSSASSEESHSSNSEnSSNSSOSSRSSRSSESSNSTSSNESESESERESSSSSTESSSESHSnSSEESHSEESSSISNSSOSEnSSRSSHSSNSISSNE SE SESSEE DESDE SERSSSIS\n\nAAG-2630461.000028",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 21916,
    "errors": [],
    "success": true
  },
  "metadata_file": {
    "file_name": "kjnw0257-info.pdf",
    "file_path": "Presentations/kjnw0257.zip/kjnw0257-info.pdf",
    "extracted_text": "=== Page 1 ===\nnull - kjnw0257 - Downloaded 31/03/2025 11:11:17 AM\nDocument Information\nTitle: PowerPoint Presentation\nURL: https://www.industrydocuments.ucsf.edu/docs/kjnw0257\nAuthor: Manoharan Dillibabu\nDocument Date: 2020 February 27\nType: Presentation\nGenre: Microsoft Office PowerPoint Open XML Format\nPages: 29\nID: kjnw0257\nCollection: McKinsey Documents\nDrug: Oxymorphone\nAvailability: public; no restrictions\nBates Number: MCK-MAAG-2630461\nRedacted: yes\nDate Added UCSF: 2022 June 06\nCite This Document\nAuthor. Title. Date. Year. Collection. Source. https://www.industrydocuments.ucsf.edu/docs/[ID]\nManoharan Dillibabu. PowerPoint Presentation. 2020 February 27. McKinsey Documents. \nUnknown. https://www.industrydocuments.ucsf.edu/docs/kjnw0257",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 753,
    "errors": [],
    "success": true
  },
  "processed_at": "2025-06-12T12:08:47.263112"
}